Comparison Overview

AbbVie

VS

Hetero Drugs Ltd

AbbVie

1 Waukegan Road, None, North Chicago, Illinois, US, 60064
Last Update: 2025-12-11
Between 800 and 849

AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, eye care, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 58,020
Subsidiaries: 15
12-month incidents
0
Known data breaches
1
Attack type number
1

Hetero Drugs Ltd

India Hyderabad, 500018, IN
Last Update: 2025-12-09
Between 750 and 799

Hetero is a research based global pharmaceutical company focused on development, manufacturing and marketing of Active Pharmaceutical Ingredients (APIs), Intermediate Chemicals & Finished Dosages. Ever since its establishment in 1993, Hetero showed a tradition of excellence and deep sense of commitment in developing cost effective processes to offer wide range of affordable drugs.

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 10,001
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/abbvie.jpeg
AbbVie
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/hetero-drugs-ltd.jpeg
Hetero Drugs Ltd
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
AbbVie
100%
Compliance Rate
0/4 Standards Verified
Hetero Drugs Ltd
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for AbbVie in 2025.

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Hetero Drugs Ltd in 2025.

Incident History — AbbVie (X = Date, Y = Severity)

AbbVie cyber incidents detection timeline including parent company and subsidiaries

Incident History — Hetero Drugs Ltd (X = Date, Y = Severity)

Hetero Drugs Ltd cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/abbvie.jpeg
AbbVie
Incidents

Date Detected: 6/2023
Type:Breach
Attack Vector: Exploitation of Vulnerability
Motivation: Financial gain
Blog: Blog
https://images.rankiteo.com/companyimages/hetero-drugs-ltd.jpeg
Hetero Drugs Ltd
Incidents

No Incident

FAQ

AbbVie company demonstrates a stronger AI Cybersecurity Score compared to Hetero Drugs Ltd company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

AbbVie company has historically faced a number of disclosed cyber incidents, whereas Hetero Drugs Ltd company has not reported any.

In the current year, Hetero Drugs Ltd company and AbbVie company have not reported any cyber incidents.

Neither Hetero Drugs Ltd company nor AbbVie company has reported experiencing a ransomware attack publicly.

AbbVie company has disclosed at least one data breach, while the other Hetero Drugs Ltd company has not reported such incidents publicly.

Neither Hetero Drugs Ltd company nor AbbVie company has reported experiencing targeted cyberattacks publicly.

Neither AbbVie company nor Hetero Drugs Ltd company has reported experiencing or disclosing vulnerabilities publicly.

Neither AbbVie nor Hetero Drugs Ltd holds any compliance certifications.

Neither company holds any compliance certifications.

AbbVie company has more subsidiaries worldwide compared to Hetero Drugs Ltd company.

AbbVie company employs more people globally than Hetero Drugs Ltd company, reflecting its scale as a Pharmaceutical Manufacturing.

Neither AbbVie nor Hetero Drugs Ltd holds SOC 2 Type 1 certification.

Neither AbbVie nor Hetero Drugs Ltd holds SOC 2 Type 2 certification.

Neither AbbVie nor Hetero Drugs Ltd holds ISO 27001 certification.

Neither AbbVie nor Hetero Drugs Ltd holds PCI DSS certification.

Neither AbbVie nor Hetero Drugs Ltd holds HIPAA certification.

Neither AbbVie nor Hetero Drugs Ltd holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

FreePBX Endpoint Manager is a module for managing telephony endpoints in FreePBX systems. Versions prior to 16.0.96 and 17.0.1 through 17.0.9 have a weak default password. By default, this is a 6 digit numeric value which can be brute forced. (This is the app_password parameter). Depending on local configuration, this password could be the extension, voicemail, user manager, DPMA or EPM phone admin password. This issue is fixed in versions 16.0.96 and 17.0.10.

Risk Information
cvss4
Base: 6.9
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:L/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

Neuron is a PHP framework for creating and orchestrating AI Agents. In versions 2.8.11 and below, the MySQLWriteTool executes arbitrary SQL provided by the caller using PDO::prepare() + execute() without semantic restrictions. This is consistent with the name (“write tool”), but in an LLM/agent context it becomes a high-risk capability: prompt injection or indirect prompt manipulation can cause execution of destructive queries such as DROP TABLE, TRUNCATE, DELETE, ALTER, or privilege-related statements (subject to DB permissions). Deployments that expose an agent with MySQLWriteTool enabled to untrusted input and/or run the tool with a DB user that has broad privileges are impacted. This issue is fixed in version 2.8.12.

Risk Information
cvss3
Base: 9.4
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:H/A:H
Description

Neuron is a PHP framework for creating and orchestrating AI Agents. Versions 2.8.11 and below use MySQLSelectTool, which is vulnerable to Read-Only Bypass. MySQLSelectTool is intended to be a read-only SQL tool (e.g., for LLM agent querying, however, validation based on the first keyword (e.g., SELECT) and a forbidden-keyword list does not block file-writing constructs such as INTO OUTFILE / INTO DUMPFILE. As a result, an attacker who can influence the tool input (e.g., via prompt injection through a public agent endpoint) may write arbitrary files to the DB server if the MySQL/MariaDB account has the FILE privilege and server configuration permits writes to a useful location (e.g., a web-accessible directory). This issue is fixed in version 2.8.12.

Risk Information
cvss3
Base: 8.2
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:H/A:N
Description

Okta Java Management SDK facilitates interactions with the Okta management API. In versions 11.0.0 through 20.0.0, race conditions may arise from concurrent requests using the ApiClient class. This could cause a status code or response header from one request’s response to influence another request’s response. This issue is fixed in version 20.0.1.

Risk Information
cvss3
Base: 8.4
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:L/UI:N/S:C/C:H/I:H/A:L
Description

The Auth0 Next.js SDK is a library for implementing user authentication in Next.js applications. When using versions 4.11.0 through 4.11.2 and 4.12.0, simultaneous requests on the same client may result in improper lookups in the TokenRequestCache for the request results. This issue is fixed in versions 4.11.2 and 4.12.1.

Risk Information
cvss3
Base: 5.4
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:L/UI:R/S:U/C:H/I:L/A:N